• The Oncology Institute repaid its outstanding $86 million senior secured convertible note with Deerfield Partners through a refinancing.
• Debt repayment funded by a new $75 million term loan from OrbiMed, maturing in 2031.
• Used about $11 million of balance-sheet cash to complete the repayment; no additional equity raised.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Oncology Institute Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001079973-26-000934), on July 07, 2026, and is solely responsible for the information contained therein.